Skip to main content
. 2018 Nov 16;16:56. doi: 10.1186/s12962-018-0162-3

Fig. 2.

Fig. 2

Cost effective frontier: a secukinumab 150 mg, b secukinumab 300 mg, c secukinumab 300 mg. ADA, adalimumab; APR, apremilast; BS, biosimilar; CER P, certolizumab pegol; ETN, etanercept; GOL, golimumab; INF, infliximab; PsA, Psoriatic arthritis; QALYs, quality adjusted life years; SEC, secukinumab; UST, ustekinumab